Renal Cell Carcinoma

 

Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy

Investigator: Scott Tykodi, M.D., Ph.D.;   Conditions: Renal Cell Carcinoma;    Status: Recruiting;   Study ID: NCT01235962